Scenic Biotech and Stanford University Collaboration Featured in Drug Target Review

Drug 1 small

Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.

Read article

Go to news overview